133 related articles for article (PubMed ID: 38865481)
21. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Modulation of Microglial Inflammatory Gene Loci in Helminth-Induced Immune Suppression: Implications for Immune Regulation in Neurocysticercosis.
Chauhan A; Quenum FZ; Abbas A; Bradley DS; Nechaev S; Singh BB; Sharma J; Mishra BB
ASN Neuro; 2015; 7(4):. PubMed ID: 26148848
[TBL] [Abstract][Full Text] [Related]
23. Enhanced CD8 T-cell anti-viral function and clinical disease in B7-H1-deficient mice requires CD4 T cells during encephalomyelitis.
Phares TW; Stohlman SA; Hinton DR; Bergmann CC
J Neuroinflammation; 2012 Dec; 9():269. PubMed ID: 23237504
[TBL] [Abstract][Full Text] [Related]
24. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
[TBL] [Abstract][Full Text] [Related]
25. The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus.
Jin YH; Hou W; Kang HS; Koh CS; Kim BS
J Virol; 2013 Nov; 87(21):11538-51. PubMed ID: 23966393
[TBL] [Abstract][Full Text] [Related]
26. Neuroinflammatory changes of the normal brain tissue in cured mice following combined radiation and anti-PD-1 blockade therapy for glioma.
Clausi MG; Stessin AM; Zhao Z; Tsirka SE; Ryu S
Sci Rep; 2021 Mar; 11(1):5057. PubMed ID: 33658642
[TBL] [Abstract][Full Text] [Related]
27. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
[TBL] [Abstract][Full Text] [Related]
28. Programmed death 1 deficiency induces the polarization of macrophages/microglia to the M1 phenotype after spinal cord injury in mice.
Yao A; Liu F; Chen K; Tang L; Liu L; Zhang K; Yu C; Bian G; Guo H; Zheng J; Cheng P; Ju G; Wang J
Neurotherapeutics; 2014 Jul; 11(3):636-50. PubMed ID: 24853068
[TBL] [Abstract][Full Text] [Related]
29. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
30. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
31. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
32. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
33. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
34. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice.
Zhao P; Xu Y; Fan X; Li L; Li X; Arase H; Tong Q; Zhang N; An Z
MAbs; 2022; 14(1):2107971. PubMed ID: 35921534
[TBL] [Abstract][Full Text] [Related]
35. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack MH; Betof A; Dearden H; Rapazzo K; Valentine I; Brohl AS; Ancell KK; Long GV; Menzies AM; Eroglu Z; Johnson DB; Shoushtari AN
Ann Oncol; 2018 Jan; 29(1):250-255. PubMed ID: 29045547
[TBL] [Abstract][Full Text] [Related]
36. SYK regulates macrophage MHC-II expression via activation of autophagy in response to oxidized LDL.
Choi SH; Gonen A; Diehl CJ; Kim J; Almazan F; Witztum JL; Miller YI
Autophagy; 2015; 11(5):785-95. PubMed ID: 25946330
[TBL] [Abstract][Full Text] [Related]
37. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
38. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN; Bai X; Quah T; Lo SN; Allayous C; Callaghan S; Martínez-Vila C; Wallace R; Bhave P; Reijers ILM; Thompson N; Vanella V; Gerard CL; Aspeslagh S; Labianca A; Khattak A; Mandala M; Xu W; Neyns B; Michielin O; Blank CU; Welsh SJ; Haydon A; Sandhu S; Mangana J; McQuade JL; Ascierto PA; Zimmer L; Johnson DB; Arance A; Lorigan P; Lebbé C; Carlino MS; Sullivan RJ; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):917-925. PubMed ID: 33798657
[TBL] [Abstract][Full Text] [Related]
39. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS
Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo effect of PD-1/PD-L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis.
Che YM; Zhang Y; Li M; Li XP; Zhang LL
J Cell Biochem; 2018 Apr; 119(4):3044-3057. PubMed ID: 29058791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
